AML1 (Phospho-Ser303) Antibody

Catalog Number:

12003

Amount:

100μg

Price:

$319

Swiss-Prot No:

Swiss-Prot#: Q01196;
NCBI Gene#: 861;
NCBI Protein#: NP_001001890.1

Form of Antibody:

Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage/Stability:

Immunogen:

Peptide sequence around phosphorylation site of serine 303 (T-A-F(p)-S-D) derived from Human AML1.

Purification:

Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi

Specificity/Sensitivity:

The antibody detects endogenous level of AML1 only when phosphorylated at Serine 303.

Applications:

WB

Background:

CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B-dependent transcriptional activation.

References:

appl_detail:

Predicted MW: 50kd
Western blotting: 1:500~1:1000

Datasheet PDF